Education
About Us
Working with TipRanks
Follow Us
Medicenna Therapeutics Corp (TSE:MDNA)
TSX:MDNA
RESEARCH TOOLSreports
Total Valuation
Medicenna Therapeutics Corp has a market cap or net worth of C$71.18M. The enterprise value is C$53.09M.
Market CapC$71.18M
Enterprise ValueC$53.09M
Share Statistics
Medicenna Therapeutics Corp has 78,215,750 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding78,215,750
Owned by Insiders―
Owned by Institutions―
Financial Efficiency
Medicenna Therapeutics Corp’s return on equity (ROE) is -4.91 and return on invested capital (ROIC) is -120.85%.
Return on Equity (ROE)-4.91
Return on Assets (ROA)-1.33
Return on Invested Capital (ROIC)-120.85%
Return on Capital Employed (ROCE)-1.21
Revenue Per Employee0.00
Profits Per Employee-1.59M
Employee Count16
Asset Turnover0.00
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of Medicenna Therapeutics Corp is -4.95. Medicenna Therapeutics Corp’s PEG ratio is -1.17.
PE Ratio-4.95
PS Ratio0.00
PB Ratio4.74
Price to Fair Value24.28
Price to FCF-5.06
Price to Operating Cash Flow-5.06
PEG Ratio-1.17
Income Statement
In the last 12 months, Medicenna Therapeutics Corp had revenue of 0.00 and earned -25.47M in profits. Earnings per share was -0.37.
Revenue0.00
Gross Profit-5.00K
Operating Income-19.66M
Pretax Income-25.47M
Net Income-25.47M
EBITDA-18.67M
Earnings Per Share (EPS)-0.37
Cash Flow
In the last 12 months, operating cash flow was -16.34M and capital expenditures -33.00K, giving a free cash flow of -16.37M billion.
Operating Cash Flow-16.34M
Free Cash Flow-16.37M
Free Cash Flow per Share-0.21
Dividends & Yields
Medicenna Therapeutics Corp pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta1.51
52-Week Price Change-60.50%
50-Day Moving Average1.01
200-Day Moving Average1.52
Relative Strength Index (RSI)39.55
Average Volume (3m)39.53K
Important Dates
Medicenna Therapeutics Corp upcoming earnings date is Jun 25, 2025, TBA Not Confirmed.
Last Earnings DateFeb 13, 2025
Next Earnings DateJun 25, 2025
Ex-Dividend Date―
Financial Position
Medicenna Therapeutics Corp as a current ratio of 6.66, with Debt / Equity ratio of 1.00%
Current Ratio6.66
Quick Ratio6.66
Debt to Market Cap0.00
Net Debt to EBITDA0.91
Interest Coverage Ratio0.00
Taxes
In the past 12 months, Medicenna Therapeutics Corp has paid 0.00 in taxes.
Income Tax0.00
Effective Tax Rate0.00
Enterprise Valuation
Medicenna Therapeutics Corp EV to EBITDA ratio is -5.84, with an EV/FCF ratio of -6.71.
EV to Sales0.00
EV to EBITDA-5.84
EV to Free Cash Flow-6.71
EV to Operating Cash Flow-6.71
Balance Sheet
Medicenna Therapeutics Corp has C$30.00M in cash and marketable securities with C$174.00K in debt, giving a net cash position of -C$29.82M billion.
Cash & Marketable SecuritiesC$30.00M
Total DebtC$174.00K
Net Cash-C$29.82M
Net Cash Per Share-C$0.38
Tangible Book Value Per ShareC$0.07
Margins
Gross margin is 80.00%, with operating margin of 0.00%, and net profit margin of 0.00%.
Gross Margin80.00%
Operating Margin0.00%
Pretax Margin0.00%
Net Profit Margin0.00%
EBITDA Margin0.00%
EBIT Margin0.00%
Analyst Forecast
The average price target for Medicenna Therapeutics Corp is C$5.99, which is 11.43% higher than the current price. The consensus rating is Moderate Buy
Price TargetC$5.99
Price Target Upside558.24% Upside
Analyst ConsensusModerate Buy
Analyst Count2
Revenue Growth Forecast―
EPS Growth Forecast-67.03%